{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.386","upperLimit":"0.485","value":"0.436"},{"groupId":"OG001","lowerLimit":"0.370","upperLimit":"0.541","value":"0.456"},{"groupId":"OG002","lowerLimit":"0.181","upperLimit":"0.329","value":"0.253"}]}],"title":"12-Month Survival Rate"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.254","upperLimit":"0.347","value":"0.300"},{"groupId":"OG001","lowerLimit":"0.249","upperLimit":"0.417","value":"0.332"},{"groupId":"OG002","lowerLimit":"0.101","upperLimit":"0.230","value":"0.163"}]}],"title":"18-Month Survival Rate"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.172","upperLimit":"0.261","value":"0.216"},{"groupId":"OG001","lowerLimit":"0.160","upperLimit":"0.315","value":"0.235"},{"groupId":"OG002","lowerLimit":"0.080","upperLimit":"0.200","value":"0.137"}]}],"title":"24-Month Survival Rate"}],"denoms":[{"counts":[{"groupId":"OG000","value":"403"},{"groupId":"OG001","value":"137"},{"groupId":"OG002","value":"136"}],"units":"Participants"}],"description":"The probability that a subject is alive at 12 months, 18 months, and 24 months following randomization, estimated via the non-parametric method (Kaplan-Meier method). For calculating 95% CI, bootstrap method was used with 20000 simulated trials.","dispersionType":"95% Confidence Interval","groups":[{"description":"Ipilimumab was administered at a dosage of 3 mg/kg as an intravenous (IV) infusion administered over 90 minutes every 3 weeks for a total of 4 doses, together with gp100. Gp100 consisted of 2 separate peptide components: Peptide A, a peptide with sequence YLEPGPVTV (gp100:280-288\\[288V\\]) and Peptide B, a peptide with the sequence IMDQVPFSV (gp100:209-217\\[210M\\]). Each peptide was prepared with Montanide ISA-51. One dose of gp100 consisted of the administration of Peptide A, at a dosage of 2 mL or 1 mg, and Peptide B, at a dosage of 2 mL or 1 mg. After Week 12, subjects who met re-induction criteria could receive further cycles of their randomized study therapy.","id":"OG000","title":"Ipilimumab Plus gp100"},{"description":"Ipilimumab was administered at a dosage of 3 mg/kg as an intravenous (IV) infusion administered over 90 minutes every 3 weeks for a total of 4 doses, together with matching vaccine placebo. The vaccine placebo consisted of sterile 0.9% sodium chloride. After Week 12, subjects who met re-induction criteria could receive further cycles of their randomized study therapy.","id":"OG001","title":"Ipilimumab Monotherapy"},{"description":"Gp100 consisted of 2 separate peptide components: Peptide A, a peptide with sequence YLEPGPVTV (gp100:280-288\\[288V\\]) and Peptide B, a peptide with the sequence IMDQVPFSV (gp100:209-217\\[210M\\]). Each peptide was prepared with Montanide ISA-51. One dose of gp100 consisted of the administration of Peptide A, at a dosage of 2 mL or 1 mg, and Peptide B, at a dosage of 2 mL or 1 mg. After Week 12, subjects who met re-induction criteria could receive further cycles of their randomized study therapy.","id":"OG002","title":"gp100"}],"paramType":"NUMBER","populationDescription":"Intent-to-treat population, as randomized. All subjects who were randomized to any treatment group in the study.","reportingStatus":"POSTED","timeFrame":"Month 12, Month 18, Month 24","title":"12-, 18-, and 24-Month Survival Rates","type":"SECONDARY","unitOfMeasure":"probability"}